Roche's H1 profit surges 18.5% to 8.9B Swiss francs

Thursday, 25. July 2019 09:58

Roche Holding AG said on Thursday that it boosted sales by 8.4% in the first six months of the year on an annual scale to 30.47 billion Swiss francs. The Basel-based producer of pharmaceuticals revealed the diagnostics division lagged by bringing 6.28 billion or just 0.2% more than in the same period of 2018. Take away the currency impact and the rise was 9% and 2%, respectively, on a rounded basis. Net income in terms of International Financial Reporting Standards jumped 18.5% to 8.9 billion Swiss francs or 17.4% to 9.99 Swiss francs per diluted share.

The parent of F. Hoffmann-La Roche AG reported a jump in core operating profit by 10.8% year over year to 12.36 billion Swiss francs or 13% to 11.12 per share and the results were insignificantly different at constant exchange rates. Shares were 1.27% in the green at 9:43 am CET at 267.15 Swiss francs.

"In the first half of the year, we achieved very strong results, driven by high demand for our new medicines. I am very pleased with the expedited approvals health authorities granted for Polivy and Rozlytrek," chief executive Severin Schwan said. Guidance was upgraded for the second time this year from sales growth in mid-single digits to mid- to high single digits independent of currency changes with the intention to raise dividends

Related Links: Roche HoldingRoche Holding
Author:
Breaking the News / IT